Riluzole | Sodium channel blocker / Neuroprotective
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 20 mg | $38.00 | ||
| 100 mg | $140.00 |
Riluzole (1744-22-5) is a clinically useful drug for the treatment of amyotrophic lateral sclerosis (ALS).1 Riluzole inhibits glutamate release via inactivation of voltage-dependent ion channels, effects expression and signal transduction of glutamate receptors, and facilitates glutamate uptake.2,3,4 It has also been investigated as a treatment for depression and anxiety.5 Riluzole induced apoptosis in mGluR1-expressing melanoma cells6, inhibited cell proliferation in a U87MG glioblastoma model via blockage of glutamate release7, and inhibited the growth of brain tumor stem-like cells via downregulation of GLUT3.8
References/Citations:
1) Bellingham (2011), A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade; CNS Neurosci. Ther. 17 4
2) Urbani and Belluzzi (2000), Riluzole inhibits the persistent sodium current in mammalian CNS neurons; Eur. J. Neurosci. 12 3567
3) Frizzo et al. (2004), Riluzole enhances glutamate uptake in rat astrocyte cultures; Cell Mol. Neurobiol. 24 123
4) Doble (1996), The pharmacology and mechanism of action of riluzole; Neurology 47 S233
5) Pittenger et al. (2008), Riluzole in the treatment of mood and anxiety disorders; CNS Drugs 22 761
6) Namkoong et al. (2007), Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma; Cancer Res. 67 2298
7) Zhang et al. (2015), Anti-cancer effect of metabotropic glutamate receptor inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway; Cell Physiol. Biochem. 35 419
8) Sperling et al. (2017), Riluzole: a potential therapeutic intervention in human brain tumor stem-like cells; Oncotarget 8 96697
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Riluzole (1744-22-5) is a clinically useful drug for the treatment of amyotrophic lateral sclerosis (ALS).1 Riluzole inhibits glutamate release via inactivation of voltage-dependent ion channels, effects expression and signal transduction of glutamate receptors, and facilitates glutamate uptake.2,3,4 It has also been investigated as a treatment for depression and anxiety.5 Riluzole induced apoptosis in mGluR1-expressing melanoma cells6, inhibited cell proliferation in a U87MG glioblastoma model via blockage of glutamate release7, and inhibited the growth of brain tumor stem-like cells via downregulation of GLUT3.8
References/Citations:
1) Bellingham (2011), A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade; CNS Neurosci. Ther. 17 4
2) Urbani and Belluzzi (2000), Riluzole inhibits the persistent sodium current in mammalian CNS neurons; Eur. J. Neurosci. 12 3567
3) Frizzo et al. (2004), Riluzole enhances glutamate uptake in rat astrocyte cultures; Cell Mol. Neurobiol. 24 123
4) Doble (1996), The pharmacology and mechanism of action of riluzole; Neurology 47 S233
5) Pittenger et al. (2008), Riluzole in the treatment of mood and anxiety disorders; CNS Drugs 22 761
6) Namkoong et al. (2007), Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma; Cancer Res. 67 2298
7) Zhang et al. (2015), Anti-cancer effect of metabotropic glutamate receptor inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway; Cell Physiol. Biochem. 35 419
8) Sperling et al. (2017), Riluzole: a potential therapeutic intervention in human brain tumor stem-like cells; Oncotarget 8 96697
Related products
-
Zafirlukast | HSP70 inhibitor and leukotriene antagonist
From $28.00CAS:107753-78-6Catalog Number:10-1100Activity:Hsp70 inhibitorAlternate Names:ICI-204219Molecular Weight:575.69Molecular Formula:C31H33N3O6SSolubility:Soluble in DMSO (up to 10 mg/ml).Physical Properties:White or pink solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 2 years as supplied. Protect from exposure to moisture. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
Sivelestat sodium | Leukocyte elastase inhibitor
From $54.00CAS:201677-61-4Catalog Number:10-1102Activity:Leukocyte elastase inhibitorAlternate Names:ONO-5046Chemical Name:N-{2-[({4-[(2,2-Dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine sodium hydrateMolecular Weight:528.51Molecular Formula:C20H21N2O7S·Na·4H2OSolubility:Soluble in DMSO (up to 20 mg/ml).Physical Properties:White solidPurity:98% by HPLCStorage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 monthsShipping Code:RT -
Sunitinib malate | VEGFR, PDGFR kinase inhibitor
From $60.00CAS:341031-54-7Catalog Number:10-1078Activity:VEGFR, PDGFR kinase inhibitorAlternate Names:SU-11248Chemical Name:N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide malateMolecular Weight:532.57Molecular Formula:C22H27FN4O4 C4H6O5Solubility:Soluble in DMSO (up to 13 mg/ml).Physical Properties:Orange solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
